TY - JOUR
T1 - A single medical marker for diagnosis of methamphetamine addiction-dna methylation of SHATI/NAT8L promoter sites from patient blood
AU - Yuka, Kusui
AU - Nishizawa, Daisuke
AU - Hasegawa, Junko
AU - Uno, Kyosuke
AU - Miyanishi, Hajime
AU - Ujike, Hiroshi
AU - Ozaki, Norio
AU - Inada, Toshiya
AU - Iwata, Nakao
AU - Sora, Ichiro
AU - Iyo, Masaomi
AU - Yamada, Mitsuhiko
AU - Kondo, Naoki
AU - Won, Moo Jun
AU - Naruse, Nobuya
AU - Uehara-Aoyama, Kumi
AU - Ikeda, Kazutaka
AU - Nitta, Atsumi
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2019
Y1 - 2019
N2 - Background: Methamphetamine (METH) is one of the most widely distributed psychostimulants worldwide. Despite active counter measures taken by different countries, neither overall usage of METH nor the frequency of repeat users has reduced over the past decade. METH induces abuse and dependence as it acts on the central nervous system and temporarily stimulates the brain. The recidivism rate for abuse of stimulants in Japan is very high and therefore prevention of repeated usage is paramount. However, we lack information about the relationship between METH users and genomic changes in humans in Japan, which would provide important information to aid such efforts. Objective: Shati/Nat8l is a METH-inducible molecule and its overexpression has protective effects on the brain upon METH usage. Here we investigated the effect of METH usage on DNA methylation rates at the promoter site of SHATI/NAT8L. We used DNA samples from human METH users, who are usually difficult to recruit in Japan. Methods: We measured DNA methylation at SHATI/NAT8L promoter sites by pyrosequencing method using 193 samples of METH users and 60 samples of healthy subjects. In this method, DNA methylation is measured by utilizing the property that only non-methylated cytosine changes to urasil after bisulfite conversion. Results: We found that the rate of DNA methylation at six CpG islands of SHATI/NAT8L promoter sites is significantly higher in METH users when compared to healthy subjects. Conclusion: These results suggest that the DNA methylation rate of SHATI/NAT8L promotor regions offers a new diagnostic method for METH usage.
AB - Background: Methamphetamine (METH) is one of the most widely distributed psychostimulants worldwide. Despite active counter measures taken by different countries, neither overall usage of METH nor the frequency of repeat users has reduced over the past decade. METH induces abuse and dependence as it acts on the central nervous system and temporarily stimulates the brain. The recidivism rate for abuse of stimulants in Japan is very high and therefore prevention of repeated usage is paramount. However, we lack information about the relationship between METH users and genomic changes in humans in Japan, which would provide important information to aid such efforts. Objective: Shati/Nat8l is a METH-inducible molecule and its overexpression has protective effects on the brain upon METH usage. Here we investigated the effect of METH usage on DNA methylation rates at the promoter site of SHATI/NAT8L. We used DNA samples from human METH users, who are usually difficult to recruit in Japan. Methods: We measured DNA methylation at SHATI/NAT8L promoter sites by pyrosequencing method using 193 samples of METH users and 60 samples of healthy subjects. In this method, DNA methylation is measured by utilizing the property that only non-methylated cytosine changes to urasil after bisulfite conversion. Results: We found that the rate of DNA methylation at six CpG islands of SHATI/NAT8L promoter sites is significantly higher in METH users when compared to healthy subjects. Conclusion: These results suggest that the DNA methylation rate of SHATI/NAT8L promotor regions offers a new diagnostic method for METH usage.
UR - http://www.scopus.com/inward/record.url?scp=85081235124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081235124&partnerID=8YFLogxK
U2 - 10.2174/1381612826666200110111703
DO - 10.2174/1381612826666200110111703
M3 - Article
C2 - 31924153
AN - SCOPUS:85081235124
SN - 1381-6128
VL - 26
SP - 260
EP - 264
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 2
ER -